Inmune Bio Completes Phase 2 Trial for CORDStrom

Inmune Bio ( (INMB) ) just unveiled an update.

INmune Bio Inc. announced the completion of a Phase 2 clinical trial for its CORDStrom platform, designed to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. The trial demonstrated that CORDStrom was safe, well-tolerated, and provided clinical benefit, particularly in alleviating itch, a significant problem for RDEB patients. The company is preparing to submit a Biologics License Application to the FDA by the end of 2025, aiming for potential approval and market launch in 2026, which could significantly impact their market positioning and offer a novel treatment option for this unmet medical need.

More about Inmune Bio

INmune Bio Inc. operates in the biotechnology industry, focusing on developing treatments for inflammation and immunology. The company specializes in platforms like XPro, CORDStrom, and INKmune, targeting diseases such as Alzheimer’s, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and metastatic castrate-resistant prostate cancer.

YTD Price Performance: 94.62%

Average Trading Volume: 330,582

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $212.7M

See more insights into INMB stock on TipRanks’ Stock Analysis page.